Overview

Raltegravir Intensification in HIV-infected Patients

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with Raltegravir further decreases HIV viral replication in HAART-suppressed, HIV-infected patients, potentially improving immune response to antiretroviral therapy.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Raltegravir Potassium